STUDY SNAPSHOT
Who or what was studied?
People with moderate-to-severe dry eye.
What was measured?
Ocular discomfort and corneal staining.
What the selected report found
A randomized phase 2 study of RGN-259 eye drops did not find a significant difference on its two primary endpoints. Some secondary measures improved.
Eye-drop research on thymosin β4 cannot validate an injectable item labelled TB-500. Exact sequence, formulation and route must match.
Names need a molecular definition
An analytical publication identified an acetylated seven-amino-acid fragment in the TB-500 preparation it tested. That is a reason to request the exact sequence and identity documentation for a specific product, rather than assume that every use of the label denotes the same material.
Read the TB-500 analytical identification paper
Source trail
Sosne & Ousler · Clinical Ophthalmology · 2015
This is a selected-source reading brief, not a comprehensive literature review, product verification or recommendation to use a compound.